Introduction {#Sec1}
============

Family history is one of the strongest risk factors for breast cancer \[[@CR1]\]. It has been shown that the heritability of this disease is ∼30% \[[@CR2]\]. The most important determinants of risk for breast cancer are related to endogenous hormone levels and major reproductive events \[[@CR3]\], thus, suggesting that genes in the estrogen pathway may influence breast cancer risk.

The estrogen receptor alpha (ESR1) is one of the most important mediators of hormonal response in estrogen-sensitive tissues such as the breast \[[@CR4]\] and plays a crucial role in breast growth and differentiation as well as in the development of cancer \[[@CR5]\]. The human ESR1 gene is localized on chromosome 6q24-q27 \[[@CR6]\], it extends more than 140 kb and includes eight exons \[[@CR7]\]. The most studied variants in this gene are the *PvuII* (C/T) and *XbaI* (G/A) polymorphisms in intron 1, 397 and 351 bp upstream of exon 2 respectively \[[@CR8], [@CR9]\]. These variants have been implicated in gene expression by influencing transcription \[[@CR10]\]. While some studies have found an increased risk for the A and T alleles of the *XbaI* and *PvuII* polymorphisms \[[@CR4], [@CR9], [@CR10]\], others have found an increased risk only for the X (G) allele of *XbaI* \[[@CR11], [@CR12]\]. In addition, other studies found no effect at all for either of these polymorphisms \[[@CR4], [@CR13]\]. These alleles were correlated with high bone mineral density and height in other studies, including one performed in our study population, \[[@CR14], [@CR15]\], suggesting a stronger estrogenic effect in P(C) and X(G) allele carriers \[[@CR14]\].

The aim of our study was to evaluate the effect of these polymorphisms on breast cancer risk by performing an association analysis in a population based study of Caucasian postmenopausal women. Further, we performed meta-analyses of all available published data on these polymorphisms and the risk of breast cancer.

Materials and methods {#Sec2}
=====================

Study population and measurements {#Sec3}
---------------------------------

Our study population is part of the Rotterdam study \[[@CR16]\]. Inhabitants of the suburb of Ommoord aged 55 or older were invited to participate and 7983 agreed to do so (response rate 78.1%). Study participants signed an informed consent and the Medical Ethics Committee of the Erasmus Medical Center approved the study. Our study group was composed of 4,878 postmenopausal women. Information on risk factors such as age at entry, age at menarche, age at menopause, parity, body mass index (BMI), waist hip ratio (WHR) and hormone replacement therapy use (HRT) was retrieved at baseline through a questionnaire. BMI was calculated by dividing the weight in kilograms by the height (in meters) squared \[[@CR17]\].

Case identification and validation {#Sec4}
----------------------------------

Three different databases were used for patient identification. First, cases diagnosed by general practitioners in the research area (Ommoord) were collected (International Classification of Primary Care (code X76)). Second, the Dutch National Registry of all hospital admissions (LMR) was consulted to detect all malignancy related hospital admissions for study participants. Finally, regional pathology databases were linked to the Rotterdam Study to identify patients. Subsequently, breast cancer cases were validated by a physician on the basis of medical records of the general practitioner, discharge letters and pathology reports. Only pathologically confirmed cases were considered in the analysis. The index date was defined as the earliest date found in the pathology report.

Genotyping & data analysis {#Sec5}
--------------------------

Out of the 4,878 women participating in our study, 3,893 (80 %) were successfully genotyped for the *PvuII* and *XbaI* polymorphisms. The genotyping procedures have been described previously \[[@CR14]\]. Loss to follow up was assessed to verify it was independent of genotype. Categorical variables, such as parity and HRT, were compared between genotype groups using the chi-squared test. Continuous variables, (age at entry, age at menopause, BMI and WHR) were compared using the independent sample Mann--Whitney test. We used logistic regression to study the risk of breast cancer by ESR1 genotype. This analysis was performed using SPSS version 11, since there is no clear risk allele from the literature, we took the TT (*PvuII*) and AA (*XbaI*) genotypes as reference because they have been associated to lower sensitivity to estrogen in our population \[[@CR14]\]. We also performed a trend test to evaluate if the number of risk alleles carried had an effect on disease risk. Hardy-Weinberg equilibrium (HWE) was assessed for both polymorphisms using Markov-Chain Monte-Carlo approximation of the exact test implemented in the GENEPOP package V 3.3 \[[@CR18]\].

Meta-analysis {#Sec6}
-------------

We searched PubMed until October 2006 for all case-control studies on the association of the *PvuII* and *XbaI* polymorphisms in the ESR1 gene and breast cancer. Our search strategy was based on the keyword "breast cancer" combined with "estrogen receptor" and "polymorphism"*.* To verify that all studies were retrieved, the reference lists of all publications were searched for additional studies. We excluded studies from our analyses if the genotype frequencies in the control population were out of Hardy-Weinberg or if their data had been previously used in another study. To quantify the strength of association, pooled odds ratios (ORs) and 95% confidence intervals (CI) were calculated using the random-effects model of the DerSimonian and Laird method \[[@CR19]\]. The degree of heterogeneity between the study results was tested by the inconsistency statistic (*I*^2^). Funnel plots were used to evaluate publication bias \[[@CR20]\]. Data were analysed using Review Manager, version 4.2 (Cochrane Collaboration, Oxford, UK).

Results {#Sec7}
=======

The total loss of follow-up for the genotyped participants was 8.4% and it was not dependent on ESR1 genotype (*P* = 0.51). The genotype frequencies of both polymorphisms were in HWE proportions (*X*^2^*P* = 0.33 for *PvuII* and *X*^2^*P* = 0.31 for *XbaI*). In Table [1](#Tab1){ref-type="table"} we show the baseline characteristics of our study population. We found that all cases (incident and prevalent) were significantly younger at entry than controls (*P* \< 0.001) and also died earlier during follow-up (*P* \< 0.001), when using incident cases only we found the same significant differences (*P* for age at entry \<0.0001, *P* for age at death \<0.0001). We also found that cases had significantly fewer children than controls (*P* = 0.04). We did not find any significant differences in these baseline characteristics between genotype groups (data not shown). Table 1General characteristics of the study populationCasesControlsTotalTotal studied (%)190 (4.7%)3513 (95.3)3703Mean age of entry (SD)\*67.80 (7.7)70.36 (9.6)70.24 (9.6)Mean age at death (SD)\*77.30 (8.6)84.46 (8.7)84.12 (8.8)Mean age at menarche (SD)13.57 (1.7)13.68 (1.8)13.67 (1.8)Mean age at menopause (SD)\*49.51 (4.8)52.19 (13.6)52.07 (13.3)Mean number of children (SD)\*1.77 (1.6)2.12 (1.7)2.10 (1.7)Parity (SD) (≥1 child)\*121 (71.6)2640 (79.4)2761 (79)Hormone replacement therapy(%)27 (21.1)504 (19.5)531 (19.6)Mean BMI (SD)27.10 (3.9)26.67 (4.1)26.69 (4.1)Mean WHR (SD)0.87 (.09)0.87 (.09)0.87 (.09)\* *P*-value \< 0.05

There were 38 women with previously diagnosed postmenopausal breast cancer who entered the study. During follow-up, 152 were additionally diagnosed. There were no significant differences in the number of cases between the *PvuII* (*P* = 0.43 for overall cases) and *XbaI* genotypes (*P* = 0.33 for overall cases).

We carried out a logistic regression analysis adjusting for age at entry, age at menopause, BMI, WHR and HRT for both polymorphisms separately (Table [2](#Tab2){ref-type="table"}). Since the T and A alleles of these polymorphisms have been correlated to lower estrogenic effects, we used the TT and AA genotypes as our reference categories in the analyses. There were no significant differences in risk for breast cancer among carriers of the different genotypes of the *PvuII* or *XbaI* polymorphisms in the ESR1 gene. There was a non-significant tendency of the C allele of *PvuII* (*P*-for trend = 0.22) and G allele of the *XbaI* (*P*-for trend 0.26) to be over represented in patients. Table 2Odds ratios for breast cancer risk for *PvuII* and *XbaI* genotypesOverallIncidentPrevalent*PvuII*TTRefRefRefTC0.9 (0.6--1.4)1.0 (0.6--1.6)0.8 (0.3--2.1)CC1.4 (0.8--2.2)1.4 (0.8--2.5)1.2 (0.4--3.3)***XbaI***AARefRefRefGA1.2 (0.8--1.7)1.3 (0.8--2.0)0.8 (0.4--1.9)GG1.3 (0.7--2.2)1.5 (0.8--2.8)0.5 (0.2--2.4)

To evaluate our data together with those in the literature we performed meta-analyses. We identified nine articles studying the relation between *XbaI* and *PvuII* polymorphisms and the risk of breast cancer \[[@CR4], [@CR9]--[@CR12], [@CR21]--[@CR24]\]. We excluded from our analyses one study \[[@CR11]\], since the data was used in another study \[[@CR4]\]. Furthermore, two studies were excluded since genotype frequencies of controls were out of HWE proportions \[[@CR9], [@CR10]\]. Using the random effects model we did not find any difference in risk among *XbaI* and *PvuII* genotypes (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). High inter-study heterogeneity can render the interpretation of the results of a meta-analysis difficult and although we found high heterogeneity in the G/A versus GG comparison there was no significant heterogeneity in the other three comparisons. Additionally, the evaluation of the funnel plots did not suggest evidence for publication bias. Fig. 1Meta-Analyses ESR1 *XbaI* polymorphism and breast cancer riskFig. 2Meta Analysis ESR1 *PvuII* polymorphism and breast cancer risk

Discussion {#Sec8}
==========

We performed an association study to evaluate the relationship of two well-studied polymorphisms in the ESR1 gene and the risk of breast cancer in Caucasian postmenopausal women from the Rotterdam Study. Using logistic regression analysis, we found no evidence of effect, with only a non-significant increase in breast cancer risk for AA carriers of the *XbaI* polymorphism (overall OR = 1.3, 95% CI = 0.7--2.2) and for TT carriers of the *PvuII* variant (overall OR = 1.4, 95% CI = 0.8--2.2). Additionally we performed meta-analyses of published data to examine the effect of both polymorphisms. These meta-analyses also suggest there are no differences in risk among genotype groups of these two ESR1 variants.

The *XbaI* and *PvuII* polymorphisms are situated in intron 1 and their functionality has not yet been demonstrated. Moreover, it has been suggested their effects could be the result of high linkage disequilibrium with functional variants that affect sensitivity to estrogen \[[@CR13]\].

One of the limitations of our study is the limited number of breast cancer cases present in our population. Nevertheless, we have sufficient power (β = 0.8) to detect effects of 1.6 or higher. We further conducted meta-analyses off all studies conducted to date. Our data suggests that these two polymorphisms do not play a role in the susceptibility of breast cancer in elderly Caucasian women.
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